Abstract
BackgroundChronic kidney disease (CKD), including nephrotic syndrome, is a major cause of cardiovascular morbidity and mortality. The literature indicates that CKD is associated with profound lipid disorders due to the dysregulation of lipoprotein metabolism which progresses kidney disease. The objective of this study is to evaluate the protective effects of curcumin on dyslipidaemia associated with adenine-induced chronic kidney disease in rats.MethodsMale SD rats (n = 29) were divided into 5 groups for 24 days: normal control (n = 5, normal diet), CKD control (n = 6, 0.75% w/w adenine-supplemented diet), CUR 50 (n = 6, 50 mg/kg/day curcumin + 0.75% w/w adenine-supplemented diet), CUR 100 (n = 6, 100 mg/kg/day curcumin + 0.75% w/w adenine-supplemented diet), and CUR 150 (n = 6, 150 mg/kg/day curcumin + 0.75% w/w adenine-supplemented diet). The serum and tissue lipid profile, as well as the kidney function test, were measured using commercial diagnostic kits.ResultsThe marked rise in total cholesterol, low-density lipoprotein (LDL) cholesterol, very low-density lipoprotein (VLDL) cholesterol, triglycerides and free fatty acids in serum, as well as hepatic cholesterol, triglyceride and free fatty acids of CKD control rats were significantly protected by curcumin co-treatment (at the dose of 50, 100 and 150 mg/kg). Furthermore, curcumin significantly increased the serum high-density lipoprotein (HDL) cholesterol compared to the CKD control rats but did not attenuate the CKD-induced weight retardation. Mathematical computational analysis revealed that curcumin significantly reduced indicators for the risk of atherosclerotic lesions (atherogenic index) and coronary atherogenesis (coronary risk index). In addition, curcumin improved kidney function as shown by the reduction in proteinuria and improvement in creatinine clearance.ConclusionThe results provide new scientific evidence for the use of curcumin in CKD-associated dyslipidaemia and substantiates the traditional use of curcumin in preventing kidney damage.
Highlights
Chronic kidney disease (CKD), including nephrotic syndrome, is a major cause of cardiovascular morbidity and mortality
While the normal control rats (n = 5) exhibited a significant increase (380.4 ± 6.0 g vs 194.2 ± 5.7 g; p < 0.001) in body weight compared with their pre-treated values at the end of the 24 days, neither the CKD control nor the curcumin-treated rats showed any significant change in body weight compared with their pre-treated values
The groups of rats treated with the various doses of curcumin (n = 6) did not show any signs of improvement in body weight compared with CKD control rats (Fig. 2 b)
Summary
Chronic kidney disease (CKD), including nephrotic syndrome, is a major cause of cardiovascular morbidity and mortality. The literature indicates that CKD is associated with profound lipid disorders due to the dysregulation of lipoprotein metabolism which progresses kidney disease. Chronic kidney disease (CKD) encompasses a spectrum of pathophysiological processes associated with abnormal kidney function (such as proteinuria) and a progressive decline in glomerular filtration rate. The current therapeutic regimens including the use of statins and fibrates have limited success in treating the associated dyslipidaemia of CKD and do not address the underlying causal factors [9]. Fibrates are indicated when hypertriglyceridaemia is the primary lipid abnormality in the CKD patient and may reduce triglyceride levels significantly [10]. Natural products have shown significant potential in improving hepatic lipid metabolism in experimentally-induced CKD [12,13,14,15]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
